LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Illumina Inc

Geschlossen

BrancheGesundheitswesen

82.66 0.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

82.09

Max

84.26

Schlüsselkennzahlen

By Trading Economics

Einkommen

-56M

131M

Verkäufe

-63M

1B

EPS

0.97

Gewinnspanne

12.584

Angestellte

8,970

EBITDA

-8M

276M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+30.25% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-3.5B

13B

Vorheriger Eröffnungskurs

82.08

Vorheriger Schlusskurs

82.66

Nachrichtenstimmung

By Acuity

50%

50%

166 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Illumina Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. März 2025, 09:18 UTC

Heiße Aktien

Stocks to Watch Tuesday: Tesla, Oracle, Delta, Nvidia -- WSJ

10. März 2025, 21:07 UTC

Top News

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

10. März 2025, 20:01 UTC

Top News

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

4. März 2025, 10:56 UTC

Heiße Aktien

Stocks to Watch Tuesday: Illumina, Nvidia, Stellantis -- WSJ

Peer-Vergleich

Kursveränderung

Illumina Inc Prognose

Kursziel

By TipRanks

30.25% Vorteil

12-Monats-Prognose

Durchschnitt 107.13 USD  30.25%

Hoch 185 USD

Tief 75 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Illumina Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

8

Buy

7

Halten

2

Sell

Technischer Score

By Trading Central

77.61 / N/AUnterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

166 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.